Japan’s Crossroads: PhRMA’s Scangos Warns Of Policy Change Fallout
This article was originally published in PharmAsia News
The foreign research-based pharma industry in Japan is continuing to ramp up warnings about what it sees as possible negative changes to Japan's currently "stable and predictable" pricing and operating environment, with the new chairman of US group PhRMA the latest to weigh in on the debate.
You may also be interested in...
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.